Revolade 50mg (Eltrombopag)

Introduction of Revolade 50mg

Revolade 50mg  is the brand term for Eltrombopag, which an oral drug is prescribed to treat some conditions that are characterized by low levels of platelets (thrombocytopenia). It’s a thrombopoietin-receptor antagonist that increases the production of platelets within the bone marrow. Revolade is most commonly used for patients suffering from chronic immune-thrombocytopenia (ITP) and thrombocytopenia in conjunction with chronic liver C infection, as well as severe anemia.

Pharmacological Action

Eltrombopag is an agonist of the blood-clotting (TPO) receptor (c-Mpl receptor) that is present on the megakaryocyte progenitor cell within the bone marrow. In stimulating these receptors, eltrombopag stimulates the growth and development of megakaryocytes that are the cells that produce platelets.

These results in increased platelet count and reduce the chance of bleeding for those with low platelet counts.

Indications

The Revolade (Eltrombopag) is recommended to be used for:

1. Chronic Immune Thrombocytopenia (ITP):
   For patients with inadequate response to corticosteroids, immunoglobulins, and splenectomy to improve platelet counts and decrease the risk of bleeding.
2. Thrombocytopenia Associated with Chronic Hepatitis C Virus (HCV) Infection:
   Allows the beginning and continuation of therapy based on interferon through the increase of platelet counts.
3. Severe Aplastic Anemia (SAA):
   When combined with immunosuppressive therapy for patients who have not had enough reaction to previous treatments.

Dosage and Administration

• The most common dose given to an ITP patient can be 50 mg every day. Dose modifications are based on the platelet count.
• If you are a patient who is of East Asian descent or who suffers from liver disease, lower dosages (usually 25 mg per day) might be advised.
• The dosage can be increased by increments of 25 mg at intervals of at least two weeks. There is a maximum of 75 mg a day.
• Tablets must be consumed with a full stomach at least 1 hour before or 2 hours post-meal in order to maximize absorption.
• Do not take dairy products, antacids, or any supplements that contain calcium, aluminum, magnesium, or iron within 4 hours after consuming them, because they can affect absorption.

Mechanism of Action

Eltrombopag connects with the transmembrane portion of the thrombopoietin subtype megakaryocytes and hematopoietic stem cells, which activates the receptor, as well as activating the JAK/STAT signaling. The signaling process increases the proliferation of megakaryocytes and differentiation, leading to an increase in platelet production.

As opposed to thrombopoietin, which is endogenous, it has a distinct binding site at the receptor. This makes it efficient even when TPO levels are high.

Pharmacokinetics

• Absorption: The bioavailability of the oral cavity is influenced by food intake and polyvalent cations. They are the best way to absorb it is on an empty stomach.
• Distribution: Approximately 99% plasma protein-bound.
• Metabolism: The liver is the main site of metabolism. It is primarily affected via Cytochrome P450 enzymes (CYP1A2, CYP2C8) and via the process of glucuronidation.
• Elimination: Most often excreted through feces. The time of half-life varies from 21 to 32 hours.

Side Effects

The most common side effects are:

• Headache
• Nausea
• Fatigue
• Upper respiratory tract infections
• Diarrhea
• Elevated liver enzymes (ALT, AST)
• Muscle or joint pain

The most serious side effects could be a result of:

• Hepatotoxicity: Monitoring of the liver’s function regularly is vital.
• Thromboembolic events: A higher risk of blood clots because of an increase in platelet counts.
• Bone marrow fibrosis: Very rare, but must be watched.
• Cataracts: Potentially increased risk: Eye exams are suggested.

Precautions and Contraindications

• Liver impairment: Take care when using this product; dosing modifications and periodic tests of liver function are required.
• Risk of thrombosis: Patients who have a previous history of thromboembolism should be under strict observation.
• Pregnancy and breastfeeding: Only limited data available; only use in cases where the potential benefits exceed risk.
• Hematologic monitoring: It is recommended to monitor platelet counts each week throughout the first treatment phase and every other week thereafter in order to keep an eye on overly high platelet counts.

Patient Counseling

People taking Revolade 50 mg must be warned:

• Take the medicine with a full stomach, and do not consume dairy or mineral supplements before the time of dosing.
• Regularly take blood tests to track the liver’s function and platelet count.
• Be aware of any strange symptoms, including severe headaches, chest pain, swelling, or other signs of bleeding.
• Beware of activities that pose an increased chance of injury because of bleeding risks until platelet counts increase.
• Tell their physician about all medications and supplements in order to stay clear of interactions.

Summary

Revolade 50mg (Eltrombopag) is a reliable oral treatment for patients suffering from thrombocytopenia caused by chronic ITP, hepatitis C, or acute anemia aplastic. Stimulating the production of platelets, it decreases the risk of bleeding and assists in better management of the disease. Continuous monitoring of platelet levels as well as liver function is vital for minimizing adverse side effects and maximizing the effectiveness of therapy.